You are here

New Strategy for Developing Alzheimer’s Disease Therapeutics

Weekly Seminar | Not Open to the Public
Who Should Attend: 


Cheng-Xin Gong's Photo
Professor and Head
Laboratory of Brain Metabolism, Inge Grundke-Iqbal Research Floor


Alzheimer’s disease (AD) is a devastating neurodegenerative disease that affects more than five million people in the US alone. Despite enormous effort on research and drug development in the last three decades, no disease-modifying therapeutics for AD have been developed. Out-of-the-box thinking and novel strategies are needed for the success of AD drug development. We recently proposed a multifactual mechanism of AD, which warrants a new strategy toward multi-targets for developing AD therapeutics. We tested several approaches in preclinical studies on the basis of this strategy. This new AD hypothesis and some of the preclinical studies will be presented in this seminar.

Cheng-Xin Gong's Figure


Cheng-Xin Gong, Fei Liu, Khalid Iqbal
Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease
J Alzheimers Dis . 2018;64(s1):S107-S117. doi: 10.3233/JAD-179921.
Hengchang Li, Chun-Ling Dai, Jin-Hua Gu, Shengwei Peng, Jian Li, Qian Yu, Khalid Iqbal, Fei Liu, Cheng-Xin Gong
Intranasal Administration of Insulin Reduces Chronic Behavioral Abnormality and Neuronal Apoptosis Induced by General Anesthesia in Neonatal Mice
Front Neurosci . 2019 Jul 11;13:706. doi: 10.3389/fnins.2019.00706. eCollection 2019.
Ying Zhao, Ran Qian, Jin Zhang, Fei Liu, Khalid Iqbal, Chun-Ling Dai, Cheng-Xin Gong
Young blood plasma reduces Alzheimer's disease-like brain pathologies and ameliorates cognitive impairment in 3×Tg-AD mice
Alzheimers Res Ther . 2020 Jun 8;12(1):70. doi: 10.1186/s13195-020-00639-w.


Tuesday, December 8, 2020 - 12:30pm


Conference Room: 
Online Webinar

More Information

Darlene White

Conditions & Recovery

Neurodegenerative Diseases icon
Worldwide, 50 million people are living with Alzheimer's and other dementias.